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Evaluation of Microparticulate Ovarian Cancer Vaccine via Transdermal Route of
Delivery
Abstract
Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality
rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic
approach with a promising antigenic delivery system without a need for conventional adjuvants. In this
study, a microparticulate vaccine using whole cell lysate of a murine ovarian cancer cell line, ID8 was
prepared by spray drying. Further, the effect of interleukins (ILs) such as IL-2 and IL-12 was evaluated in a
separate study group by administering them with vaccine particles to enhance the immune response. The
vaccine microparticles were administered to C57BL/6 female mice via transdermal alone and in
combination with the oral route. The transdermal vaccine was delivered using a metallic microneedle
device, AdminPen™. Orally administered microparticles also included an M-cell targeting ligand, Aleuria
aurantia lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer's patches of small
intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses
administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were
challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in case of
transdermal and combination of routes at the end of 15th week when compared to controls. Inclusion of
interleukins resulted in 3 times tumor suppression when administered with transdermal vaccine and
around 9 times tumor suppression for the combination route of delivery in comparison to controls. These
results were further potentiated by serum IgG, IgG1 and IgG2a titers. Moreover, CD8+ T-cell, CD4+ T-cell
and NK (natural killer) cell populations in splenocytes were elevated in case of vaccinated mice. Thus,
vaccine microparticles could trigger humoral as well as cellular immune response when administered
transdermally and via combination of route of delivery. However overall, vaccine administered with
interleukins, via combination of route, was found to be the most efficacious to suppress the tumor growth
and lead to a protective immune response.
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Abstract: Ovarian cancer is the fifth most commonly occurring malignancy in women, with the
highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as
an immunotherapeutic approach with a promising antigenic delivery system without a need for
conventional adjuvants. In this study, a microparticulate vaccine using whole cell lysate of a
murine ovarian cancer cell line, ID8 was prepared by spray drying. Further, the effect of
interleukins (ILs) such as IL-2 and IL-12 was evaluated in a separate study group by administering
them with vaccine particles to enhance the immune response. The vaccine microparticles were
administered to C57BL/6 female mice via transdermal alone and in combination with the oral
route. The transdermal vaccine was delivered using a metallic microneedle device, AdminPenTM.
Orally administered microparticles also included an M-cell targeting ligand, Aleuria aurantia
lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer's patches of small
intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses
administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were
challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in
case of transdermal and combination of routes at the end of 15th week when compared to controls.
Inclusion of interleukins resulted in 3 times tumor suppression when administered with
transdermal vaccine and around 9 times tumor suppression for the combination route of delivery
in comparison to controls. These results were further potentiated by serum IgG, IgG1 and IgG2a
titers. Moreover, CD8+ T-cell, CD4+ T-cell and NK (natural killer) cell populations in splenocytes
were elevated in case of vaccinated mice. Thus, vaccine microparticles could trigger humoral as
well as cellular immune response when administered transdermally and via combination of route
of delivery. However overall, vaccine administered with interleukins, via combination of route,
was found to be the most efficacious to suppress the tumor growth and lead to a protective immune
response.
1. Introduction:
Ovarian cancer is the most lethal gynecological cancer and the fifth most leading cause of cancer
related deaths in women in the US [1, 2]. The National Cancer Institute (NCI) has estimated
21,290 new cases and 14,180 deaths due to ovarian cancer in the US in 2015. When
cancer incidences are compared worldwide, the mortality rate associated with ovarian cancer was
found to be relatively high in the US and Europe [3]. Since it is very difficult to detect an ovarian
cancer, especially in the early stages, it is referred to as a ‘silent killer’. Only about 10% of
1

Permanent Address: Department of Pharmaceutical Sciences, Mercer University College of
Pharmacy and Health Sciences, 3001 Mercer University Drive, Atlanta, GA 30341, USA

ovarian cancers are usually found in the early stages. Patients with epithelial tumors, which
account for approximately 90% of ovarian cancer, generally have poor overall survival and the
5-year survival for stages III–IV of these tumors is about 29.1% [4]. The first-line treatment for
advanced ovarian cancer involves surgery to remove the tumor, followed by chemotherapy.
However, the cancer relapses within relatively short periods of time even after treatment. It has
been reported that up to 75% of patients responding well to the initial treatments face tumor
relapse within 18–28 months [5]. Moreover, chemotherapeutic treatments for cancer are toxic
and/or of minimal therapeutic value. Therefore, alternative approaches such as immunotherapy is
being investigated to prevent relapse of cancer. Several vaccines are underway in clinical trials
and most of them have not progressed beyond phase I/II studies [6, 7].
Various proteins and peptides have been approved or are being evaluated in clinical trials for
treatment of cancer. Due to limited oral bioavailability of such antigens, injectable routes of
administration are currently being used. Scientists have been exploring the potential of delivering
vaccine antigens orally or transdermally as these delivery routes have ease of administration, are
non-invasive and patient compliant. Transdermal delivery is considered as the best route for
vaccine administration because of the skin-associated lymphoid tissue which comprises of
Langerhans cells, dermal dendritic cells, lymph nodes and subsets of T-lymphocytes.
Microneedles have been used to pierce the upper layer- Stratum corneum of the skin to enhance
transdermal delivery by promoting the transport of macromolecules that cannot be delivered
across the skin by passive diffusion alone [8, 9]. Microneedles are micron-sized needles, which
upon insertion into the skin result in formation of aqueous conduits forming a passage for the
vaccine antigens towards the immune-competent skin layers. Due to their short needle length,
they avoid contact with the nerve endings in the dermis thus remain to be a painless mode of
immunization [10-12].
In addition, the microparticulate delivery system has several advantages over the usage of the
antigens alone. Particulate antigens have been proven to be more immunogenic than soluble
antigens [13, 14]. Improved uptake of the particles compared to the solution results in higher
cytotoxic T-lymphocytes (CTLs) response against the cancer cells. The antigen presenting cells
(APCs) in the body easily phagocytose these microparticles recognizing them as an antigen and
generate an immune response [15]. Further, they are drained into the nearby lymph nodes where
they activate various other immune cells. Thus, the particulate delivery systems may mimic
pathogens that are commonly recognized, phagocytosed and processed by professional antigenpresenting cells (APC) [16, 17]. When administered transdermally, the microparticles are taken
up by the immune cells in the skin, which trigger mucosal as well as systemic immune response
[10]. Langerhans cells are dendritic cells that activate T cells and induce a strong immune
response and occupy around 20% of the skin’s area. On the other hand, M-cells are the microfold
cells, which act as sampling ports for any foreign entities encountered in the small intestine upon
oral administration [18-23]. These M cells house various dendritic cells and immune cells in
them. Once the oral vaccine particle is sampled by M-cells, it is processed by a dendritic
cell/antigen presenting cell (APC) and presented on MHC (major histocompatibility complex)
Class I or MHC Class II molecules [24, 25]. The antigens are further recognized by the immune
cells in the vicinity leading to the cascade of an immune response. The immune response also
includes humoral response by plasma B-cells, which leads to production of antibodies and their
class switching. The role of B-cells has been debatable in past but a recent study by Mahmoud

SM et al. shows that the humoral immunity is important in addition to cell-mediated immunity in
prognosis of breast cancer [26]. Thus, we aim to trigger both humoral and cell-mediated immune
response through this prophylactic cancer vaccine, which can impart resistance against tumor
challenge. Moreover, the microparticulate drug delivery system can be used to assimilate various
antigens in one delivery system that can reduce the number of doses as well as reduce the
different vaccination regimen [13, 14].
In this study, we have investigated whether vaccination with microparticles containing the
ovarian cancer antigens can prevent/ retard ovarian cancer growth. A murine ovarian cancer cell
line, ID8 was used as a source of antigens for vaccine preparation. The cell line correlates closely
to human ovarian cancer cell lines in signaling pathways and results in development of tumor in
mice models similar to human ovarian cancer. Thus, ID8 cell line provides a unique model to
study the immune response developed by the vaccine against the initiation and progression of
ovarian cancer in mice with an intact immune system [2]. Therefore, we proceeded with a whole
cell lysate of ID8 cells to prepare the vaccine for this study. Despite of advancement in
recombinant technology and gene expression, the whole cell lysate vaccine still remains a very
promising approach. Whole cell lysate provides a pool of tumor-associated antigens (TAAs)
which can induce both CD8+ and CD4+ T cells [27].
In our previous study, microparticulate vaccine was found to be efficacious when administered
orally [23]. Therefore, we aimed to evaluate the microparticulate vaccine via transdermal route
alone and in combination with oral route. By combination route of administration, aim was to
achieve merits of both oral and transdermal immunization [28]. The vaccine particles were
administered for this purpose using a microneedle device called as AdminPenTM. For this
purpose, microparticles were prepared by spray drying technique using methacrylic copolymer
Eudragit® FS 30 D and hydroxyl propyl methyl cellulose acetate succinate (HPMCAS) as
described elsewhere [20, 23]. These polymers have been reported their applications for
transdermal delivery in form of patches as well as particulates [29, 30]. Several others have
mentioned their usage for oral sustained or controlled release delivery [31, 32]. To target the
vaccine formulation to M-cells in the Peyer’s patches of the intestine upon oral delivery, M-cell
targeting agent, Aleuria aurantia lectin (AAL) was used in the formulation [15, 20, 21]. In
addition, immunostimulatory molecules such as IL-2 and IL-12 were added in order to enhance
the overall potency of the formulated vaccines. Oral delivery was performed by using an oral
gavage. Transdermal delivery was achieved using an AdminPenTM device comprised of an array
of 43 metallic microneedles of 1100 nm length in 1 cm sq area of circular microneedle array
made of SS316 stainless steel (as shown in figure 1). In the present study, we demonstrate and
compare the efficacy of the vaccine formulation which was administered via two different
approaches based on route of administration: (1) transdermal and (2) combination of transdermal
and oral route in vivo in mouse tumor model.

Fig. 1: AdminPenTM device comprised of an array of 43 metallic microneedles of 1100 nm length
in 1 cm sq area of circular microneedle array made of SS316 stainless steel, attached to a syringe
(Image produced with a permission from AdminMed / nanoBioSciences LLC)
2. Materials and Methods
2.1.
Materials
ID8 cell line was kindly provided by Dr. Katherine Roby, Kansas University Medical Center,
Kansas City, KS. Six to eight week-old C57BL/6 female mice were purchased from Charles
River Laboratories, Wilmington, MA. HPMCAS was purchased from AQOAT, FMC
Biopolymers, Philadelphia, PA. Eudragit® FS 30 D was generously gifted by Evonik industries,
Parsippany, NJ. Mouse plasma was obtained from Biochemed, Winchester, VA. AAL was
obtained from Vector Labs, Inc., Burlingame, CA. Recombinant murine interleukins, IL-2 (5 X
106 units/mg) and IL-12 (1 X 107 units/mg) were purchased from Peprotech Inc., Rocky Hill, NJ.
Flow cytometry cell markers were purchased from eBioscience, San Diego, CA. Goat antimouse HRP-IgG and anti-IgG subtypes were purchased from Bethyl Laboratories, Montgomery,
TX and Sigma, St. Louis, MO respectively. AdminPenTM device was purchased from
nanoBioSciences LLC. All other materials used were of analytical grade.
2.2.
Preparation and characterization of whole cell lysate of ID8 ovarian cancer cell line
The whole cell lysate of the murine ovarian cancer ID8 cells was prepared using hypotonic
buffer and freeze-thaw cycles as described elsewhere [23, 33, 34]. The lysate obtained was
stored at -80⁰ C until used. The whole cell lysate of ID8 cell line was characterized for total
protein content using Bio-Rad DCTM protein assay. The lysate was also screened for presence of
the only known marker, by western blot analysis as described elsewhere [23, 35].
2.3.
Preparation and characterization of vaccine microparticles
The vaccine formulation was prepared by using spray drying technique as described elsewhere
[20]. Briefly, hydroxyl propyl methyl cellulose acetate succinate (HPMCAS) and Eudragit® FS
30D were dissolved in an alkaline solution, followed by addition of chitosan glycol. Mouse
plasma, trehalose, and tween 20 were added to the solution. Whole cell lysate obtained from ID8
cells (5%w/w) was added to this feed mixture and temperature was maintained at 4⁰ ± 2⁰ C
throughout the spraying. This aqueous solution was spray dried using Buchi B-191 Mini Spray
Dryer (Buchi Corporation, New Castle, DE) at inlet temperature 125° C, outlet temperature 80°
C, 500Nl/h, and 2% spray flow feed rate (10 mL per 30 min) of peristaltic pump, and nozzle
diameter 0.7 mm . The particles were characterized for size and charge, using laser particle
counter (Spectrex PC -2000) (n=3) and Malvern zeta sizer (ZEN 1600) (n=10) respectively.
Loading efficiency was determined by Biorad DCTM protein assay by extracting the lysate in
phosphate buffered saline.

2.4.
Immunization
The immunogenicity of microparticulate vaccine was evaluated using C57BL/6 female mice
model. The animal experiments were carried out as per approved protocols by Mercer
University’s Institutional Animal Care and Use Committee (IACUC). Animals (n=8) were
administered with microparticles as one prime dose followed by one booster after one week and
thereafter by 8 boosters with an interval of two weeks. In case of vaccine with interleukins
formulations, 4 x 105 U of IL-2 and 8 x 105 U of IL-12 were added to this particulate suspension.
For delivering microparticles via transdermal route, mice skin was shaved two days prior to
vaccination. Around 5 mg of microparticles were suspended in citrate buffer, pH 4.0 containing
PEG 8000 as a viscosity modifier [11]. These mice were vaccinated by delivering this
microparticulate suspension through AdminPenTM 1200 microneedle liquid injection system
(refer to figure 1) which allows particles to seep into microchannels created by microneedles. For
oral route, 5 mg of microparticles was suspended in citrate buffer and administered orally using
oral gavage. In case of combination of routes, mice were given 5 transdermal doses and 5 oral
doses administered alternatively, beginning with transdermal dose. In a study by ChirivaInternati et al., SP17 protein has been evaluated as an ovarian cancer vaccine in murine models,
where the mice were immunized intramuscularly with SP17 in ten doses of vaccination. It has
shown to be a promising approach prophylactically as well as therapeutically [35]. The number
of doses were decided based on the previous successful particulate vaccine studies conducted by
the group [23]. The booster doses were intended to potentiate the immune response by repeated
exposure of the antigen every alternate week. Three different formulations such as placebo,
vaccine and vaccine with interleukins were evaluated for this purpose.
2.5.
Tumor challenge study
One week after the last vaccination, the mice were challenged s.c. with 1x107 live ID8 cells as
described elsewhere [36, 37]. The cells were injected into the right back flank of mice. Tumor
development was monitored using digital Vernier calipers. The mice were euthanized whenever
the tumor ulcerated or tumors exceeded a size of 15 mm in any of the perpendicular diameters.
The tumor volume (V) was determined by using the formula, V=1/2(Length) (Width)2 [36, 38].
2.6.
Assessment of humoral (B-cell mediated) immune response in serum
The blood samples were collected prior to each dose of vaccination. Serum was analyzed by
ELISA as described elsewhere. Briefly, a 96 well plate coated with the lysate (100µg/well) was
incubated with 1: 10 dilution of serum samples. HRP-tagged secondary anti-mouse goat IgG was
then added to each well, and incubated for 1 hr. TMB substrate reagent (3,3’, 5,5”-tetramethyl
benzidine) (BD OptEIATM, BD Biosciences, CA) was added and the plate was again incubated
for 30 min. The reaction was stopped by addition of 4N H2SO4. The plate was read using
microplate reader (BioTek instruments Inc., Winooski, VT) at 450 nm. In case of IgG subtypes
analysis, serum samples were analyzed in dilution of 1:400. The plate was then incubated with
goat anti-mouse IgG subtype IgG1 or IgG2a, followed incubation with HRP-conjugated anti-goat
IgG. Thereafter, same procedure as described above for IgG titers analysis was followed.
2.7.
Determination of T-cell based/ cellular immune response
A separate group of mice was vaccinated in similar way as described in section 2.4. At the end of
vaccination, mice were euthanized and the spleens were harvested. The single cell suspension of
pooled splenocytes were stimulated for 5 days at 37⁰C with mitomycin-treated tumor cells in a

ratio 10:1 with 10 U/mL of recombinant murine IL-2. At the end of 5-days, the cells were
washed with Hank’s balanced salt solution and labeled with anti-mouse CD8a FITC (for CD8+
T-cells), anti-mouse CD4 PE (for CD4+ T-cells), and anti-mouse NK PE (for NK cells). The
cells were analyzed for the specific cell populations by flow cytometric analysis using BD
accuri® C6 flow cytometer [23].
2.8.
Statistical analysis
Serum IgG subtype titers and flow-cytometry results were analyzed using one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparison test. Tumor volume
measurements and serum IgGs were analyzed by two-way ANOVA followed by Bonferroni
multiple comparisons. All statistical analyses were performed using GraphPad Prism5 (trial
version 5.04, GraphPad Software, Inc., La Jolla, CA). For each test, p value less than 0.05 was
considered significant. Data are expressed as mean ± standard error.
3. Results and Discussion
3.1.
Preparation and characterization of the whole cell lysate
The total protein concentration of lysate was 1.56 ± 0.5 mg/mL. The western blot analysis of the
lysate showed the presence of SP17 antigen in the lysate prepared (shown elsewhere) [23]. The
only protein which is expressed by ID8 cells and that has been studied is the sperm protein
(SP17, molecular weight 15kD). It is one of the cancer/testis antigens, a sub- class of TAAs. It is
non-mutated self-antigen which is reported to be recognized by CD8+ T-cells. This protein has
been found to be expressed or over-expressed in ovarian cancers. Moreover, human SP17 shows
70% homology with murine SP17. Thus, SP17 is a promising antigen for immunotherapy in
ovarian cancer [35]. Therefore, the presence of SP17 in the lysate ensured that the protein
cocktail obtained was antigenic when given as a vaccine.
3.2.
Preparation and characterization of vaccine microparticles
The particles obtained were of 1.58 ± 0.62 µm size with a charge of 12.48 ± 2.32 mV. There was
no significant change in size and charge upon loading these particles with the lysate. The
production yield was 72.58 ± 3.41 % w/w. The loading efficiency of the particles was 92.68 ±
4.77% w/w. These microparticles were within the size range to mimic pathogenic species;
thereby enhancing the potential of naturally being phaygocytosed by dendritic cells. Thus, the
uptake would allow processing of antigen-loaded microparticles leading to MHC presentations to
the immune cells.
3.3.
Immunization suppresses tumor growth
At the end of vaccination, 107 ID8 cells were injected subcutaneously to the animals of each
study group and the tumor volumes were measured every week using digital Vernier calipers. In
the control group, mice were treated with placebo particles and the tumor developed rapidly.
However, vaccinated mice showed tumor suppression when compared to the control/ placebo
group as shown in figure 2.
Vaccine alone resulted in around 1.5 times tumor suppression in case of transdermal and
combination of routes at the end of 15th week. In case of interleukins, transdermal route showed
around 3 times of tumor suppression and combination of routes resulted in around 9 times of
tumor suppression, when compared to control mice. Transdermally vaccinated mice showed
significant retardation of tumor volume in comparison to control animals at 12th week after the

tumor challenge (p<0.05), while mice vaccinated with combination of two routes showed
significant retardation at 15th week after tumor challenge. The tumor volume measurements
(A)

(B)

obtained are shown in figure 2.
Fig.2 Immunization with vaccine microparticles suppresses tumor growth: Mean tumor volumes
for mice groups treated with two different approaches: (A) Transdermal (B) Transdermal + Oral
vaccination: Placebo, vaccine microparticles with and without interleukins. The tumor volume
was monitored with the aid of Vernier calipers on a weekly basis. Vaccinated mice showed
higher tumor suppression as compared to non-vaccinated/placebo treated mice for (A)
Transdermal (B) Transdermal + Oral vaccination groups (p<0.05), *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
In case of transdermal route, there was no significant difference between vaccine and vaccine
with interleukin groups in terms of tumor volumes. This can be due to the interleukin
concentration used in vaccine which was not high enough to retard tumor growth more than that
seen with vaccine alone. Higher concentration of interleukins might be needed to show
additional tumor suppression. However, in case of combination routes, a significant difference
was seen in tumor volumes of vaccine with and without interleukins at 12th week (p<0.05) and
15th week (p<0.0001). The interleukins were found to contribute to even more tumor suppression
when administered via oral as well as transdermal route.
3.4.

Immunization with vaccine microparticles generates humoral immune response and
interleukins influence Th1/Th2 response
In order to determine B-cell response, the serum samples collected in between doses were
analyzed by ELISA. Immunized mice showed elevated IgG titers as compared to control ones at
the end of transdermal vaccination (p<0.01) as shown in figure 3(A). For combination route
(figure 3(B)), mice vaccinated with interleukins showed elevated response as compared to
control mice (p < 0.01) and mice treated with vaccine particles alone (p < 0.05) at the end of
second dosing. At the end of vaccination, it resulted in elevated titers in vaccinated mice as
compared to control mice and incorporation of interleukins resulted in further increase in titers.

Type to
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(B)

Fig. 3: Humoral response obtained with Immunization with vaccine microparticles for mice
groups treated with two different approaches: (A) Transdermal (B) Transdermal + Oral
vaccination: Placebo, vaccine microparticles with and without interleukins. Serum IgG titers
determined by ELISA, showing higher titers at the end of final vaccination in case of mice in (A)
Transdermal (B) Transdermal + Oral vaccination groups with and without interleukins when
compared to mice treated with placebo microparticles, while only in case of combination routes,
the IgG titers were elevated even further upon addition of interleukins. (p<0.05), *p<0.05,
**p<0.01, ****p<0.0001
Serum IgG1 titers (indicative of Th2 response) and IgG2a titers (indicative of Th1 response)
were elevated in mice vaccinated with interleukins when compared to control mice in case of
both study approaches as shown in figure 4 (A, B) and 5(A, B) respectively. Thus, both subtypes

of IgGs indicate that mixed Th1 and Th2 immune response was generated in case of vaccine with
interleukins group.

Fig. 4: IgG1 humoral immune response (indicative of Th2 response) for mice groups treated with
two different approaches: (A) Transdermal (B) Transdermal + Oral vaccination: Placebo, vaccine
microparticles with and without interleukins. Serum IgG1 titers determined by ELISA, showing
higher titers in case of mice vaccinated with interleukins as compared to placebo treated/ nonvaccinated mice. Vaccine with interleukins showed even further elevation in IgG1 titers in case
of combination route of vaccination. (p<0.05), *p<0.05, **p<0.01, ***p<0.001

Fig.5. IgG2a humoral immune response (indicative of Th1 response) for mice groups treated
with two different approaches: (A) Transdermal (B) Transdermal + Oral vaccination: Placebo,
vaccine microparticles with and without interleukins. Serum IgG2a titers determined by ELISA,
showing higher titers in case of mice vaccinated with interleukins as compared to placebo
treated/ non-vaccinated mice. (p<0.05), *p<0.05
Stimulation of immune system as a function of a vaccine is mainly based on humoral and cellular
response reflected in serum and lymphatic organs of the body. Humoral response is majorly read
as IgG antibodies secreted by B-cell activation. Moreover, IgG subtypes such as IgG1 and IgG2a
were determined in serum samples which are indicative of Th2 and Th1 response respectively.
The Th1 response indicates that T-helper cells (CD4+ T-cells) are activated to trigger
macrophages and cytotoxic (CD8+) T-cells, hence further cascade of immune pathway. On the
other hand, Th2 response depicts that CD4+ T-cells are triggered to activate B- cells (humoral
arm of immune response).
Serum IgG levels were found to be elevated at the end of dosing in case of vaccinated mice via
both study approaches and interleukins showed further rise in levels of IgG only in case of
combination routes. Thus, humoral response was triggered by these particulate vaccines upon
oral and transdermal administration. Further, there was an elevation in IgG1 and IgG2a titers in
mice vaccinated with interleukins in case of both study approaches. This indicates the activation
of Th1 and Th2 response only in presence of interleukins administered via transdermal and
combination route. Vaccine treated mice did not show any elevation in titers which again
indicated the influence of interleukins mediating Th1 and Th2 pathway. Thus vaccine with
interleukins resulted in mixed response of Th1 and Th2 pathways. This humoral response
complied with tumor challenge study results where interleukins group showed further
suppression of tumor for combination routes of vaccination. Only combination route showed
increase in IgG1 and IgG2a titers along with elevated IgG titers upon vaccination with

interleukins when compared to control and mice treated with vaccine particles alone. This
complied with the findings on tumor suppression.
3.5.
Immunization generates T-cell based/ cellular immune response
The second array of cancer immune response comprises of activation of T-cytotoxic (CD8+) and
T-helper (CD4+), Natural Killer (NK) cells which contribute to cellular response. For this
purpose, splenocytes were screened for specific cell markers by flow cytometry to determine
CD8+, CD4+ T-cell and NK-cell populations and the results obtained are shown in figure 6.
In case of transdermal immunization, CD8+ T-cell populations were found to be elevated in all
vaccinated mice when compared to control group as shown in figure 6 (A). Moreover, the
inclusion of interleukins in the vaccine resulted in further elevation in this cytotoxic T-cell
population (p<0.05). In case of immunization via combination of two routes, vaccine alone did
not result in any significant increase in this cell count as shown in figure 6 (B). However,
vaccine with interleukins resulted in higher population than vaccine alone as well as control
group. This difference in CD8+ T-cells response in terms of route can be attributed to the dosing
regimen followed for transdermal (10 doses of vaccine via skin) and combination route (5 doses
of vaccine via skin and 5 doses via oral route).
In case of CD4+ T-cell titers, all vaccinated groups showed significant rise in level of these cells
as shown in figure 6 (C, D). However, further elevation in CD4+ T-cell population was not seen
upon inclusion of interleukins (p<0.05).
We also analyzed NK-cell populations in splenocytes. We found that all vaccinated mice
demonstrated higher levels of NK-cells when compared to control mice. On the other hand, in
case of transdermal vaccination, interleukins group showed lower NK-cell titers than the one
obtained in vaccine alone group. However, the incorporation of interleukins resulted in even
further elevation in case of combination routes other than transdermal vaccination as shown in
figure 6 (E and F) (p<0.05). Transdermally vaccinated mice received vaccine particles via skin
for 10 times; while combination route delivered 5 doses via skin and 5 oral doses administered
alternatively. This NK-cell activity seen in combination appeared to play a major role in tumor
suppression based upon overall analysis of immune response.

Fig. 6. T-cell based/ cellular immune response: CD8+ T-cells population determined by flow
cytometry for mice treated with (A) Transdermal (B) Transdermal + Oral vaccination; CD4+ Tcells population determined by flow cytometry for mice treated with (C) Transdermal (D)
Transdermal + Oral vaccination and NK-cells population determined by flow cytometry for mice
treated with (E) Transdermal (F) Transdermal + Oral vaccination. *p<0.05, **p<0.01,
***p<0.001
The overall results obtained are summarized in table 1 to provide a statistical comparison
between the two routes of vaccine delivery. The symbol ‘*’ is used to indicate the statistically
significant difference compared to control/ placebo mice (PL); while this difference is
represented with letter ‘a’ for comparison between vaccine (V) and vaccine with interleukins
group (V + IL). When data was analyzed for vaccinated and control/placebo mice, tumor
suppression was seen in case of both transdermal and combination routes as indicated by ‘*’.
Interleukins were found to result in further suppression only in case of combination routes as

indicated by ‘a’. Further the level of significance for each comparison is described in the table 1
caption. In case of interleukins, transdermal route showed around 3 times of tumor suppression
and combination of routes resulted in around 9 times of tumor suppression, when compared to
control mice. Thus, the combination route was found to the more effective route for suppression
of tumor when vaccine was administered along with interleukins. In order to understand the
mechanism behind this effect, we performed analysis of humoral as well as cellular response. As
indicated in Table 1, for combination route, the vaccine with interleukins group showed elevated
response in almost all humoral and cellular responses as represented by level of significance with
letter ‘a’ when compared to vaccine alone group. This effect (indicated by letter ‘a’ in table 1)
was not seen in case of transdermal vaccination to the extent seen in combination route. This
correlated with the tumor retardation response seen in case of combination route when
vaccinated with interleukins. Thus, the study concludes that the combination route of vaccine
delivery in presence of interleukins provides an improved humoral/cellular immune response that
is capable of providing protection against tumor growth, as seen with this murine model for
ovarian cancer.
The overall stimulation of humoral and cellular response upon vaccination indicates the efficacy
of the vaccine microparticles. Moreover, the immune stimulation in terms of humoral and
cellular response obtained correlated with tumor volume retardation. This study indicated that
humoral response as well as cellular response was needed for tumor suppression. This finding
correlated with the study reported by Mahmoud SM et al., where it was found that the humoral
immunity is important in addition to cell-mediated immunity in prognosis of breast cancer [26].

Table 1: Summary of results obtained from in-vivo study of ovarian cancer vaccine
microparticles via two different study approaches based on route of administration
1
at the end of 15th week, PL=Placebo, V= Vaccine, V + ILs= Vaccine with interleukins,
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, results expressed in comparison to mice treated
with placebo particles within each study approach based on route of administration
a
p<0.05, aap<0.01, aaap<0.001, aaaap<0.0001 results expressed for comparison between vaccine
and vaccine with interleukins groups within each study approach based on route of
administration
In-vivo study

Transdermal

Transdermal + Oral

PL

V

V+ ILs

PL

V

V+ ILs

Tumor volume reduction1

-

****

****

-

*
-

****
aaaa

IgG titers

-

**

**

-

**
-

****
a

IgG1 titers (Th2 type response)

-

-

*

-

-

***
aa

IgG2a titers
(Th1 type response)

-

-

*

-

-

*

CD8+ T-cell population

-

***
-

***
a

-

-

**
a

CD4+ T-cell population

-

***

***

-

***

***

NK-cell population

-

***
aaa

***
-

-

*
-

***
aaa

4. Conclusion
The efficacy of vaccine microparticles containing whole cell lysate of ID8 ovarian cancer cells in
retarding tumor growth in murine models was demonstrated in this study via two different study
approaches based on routes of administration. Thus, the microparticulate vaccine when given via
combination of oral and transdermal routes provides a promising approach in terms of costeffectiveness, ease of production and patient compatibility. Vaccine with interleukins when
administered via combination of two routes was found to result in higher tumor suppression in
correlation to cellular and humoral response as compared to other routes. This study was
performed in prophylactic setting to check the efficacy of particles, which forms the strong basis
for further studies to evaluate therapeutic efficacy of the particles in tumor bearing animals.
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